Scott Myers

Scott Myers is the Chairman of the Board at Umoja Biopharma, where he brings his significant past experiences leading a broad range of biotech and biopharmaceutical organizations. He currently serves as Chairman of the Board for Zentalis Pharmaceuticals, Convergent Therapeutics, and Dynavax Technologies. Mr. Myers has also chaired the boards of Ironshore (acquired by Collegium Pharmaceuticals) and Harpoon Therapeutics (acquired by Merck). He has a proven track record of guiding companies through significant periods of growth and clinical milestones.

Previously, Mr. Myers served as President and CEO of Viridian Therapeutics, AMAG Pharmaceuticals, Rainier Therapeutics, and Cascadian Therapeutics. Mr. Myers holds an MBA in finance from the University of Chicago’s Graduate School of Business (Booth) and a B.A. in Biology from Northwestern University.